Biocon denies plans to sell $1.5 billion generic API business
Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valued at $1.5 billion, to alleviate its debt burden. A company spokesperson clarified they were not assessing divestment options or seeking advice from bankers, countering an ET report based on insights from familiar sources.
Kiran Mazumdar Shaw Biocon Biologics Biocon Ltd Biocon Limited Generic Formulations Biocon Api Business
Source: indiatimes.com